A Phase II open-label pilot study to assess the effects of Testosterone Metered Dose Transdermal System (MDTS) administration on cognitive function in wome

Phase 2

Active, not recruiting

• Conditions: cognition; Neurological - Other neurological disorders

• Registration Number: ACTRN12608000429358
• Lead Sponsor: FemPharm Pty Ltd

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2008-08-26
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Active, not recruiting
• Sex: Female
• Target Recruitment: 10

Inclusion Criteria

Healthy postmenopausal women on stable non-oral oestrogen for at least 8 weeks

Exclusion Criteria

history of cancer exluding non-melanotic skin cancer, significant heart, liver, kidney, endocrine disease or neurological disease, androgenic alopecia, current androgen or anti-androgen therapy, epilepsy, seizures, psychiatric illness, previous neurological or head injury, intellectual disability, uncontrolled hypertension, recent major gynaecological surgery, total tesosterone levels higher than the upper limit of the normal reference range for young premenopausal women, alcohol consumption of greater than 3 standard drinks per day, if uterus in situ use of progestin other than Mirena intra-uterine device, presence of implanted metallic material or devices, severe claustrophobia

Study & Design

• Study Type: Interventional
• Study Design: Not specified